<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754780</url>
  </required_header>
  <id_info>
    <org_study_id>1835-99</org_study_id>
    <secondary_id>MC0077</secondary_id>
    <secondary_id>Mayo Pirfenidone Study</secondary_id>
    <nct_id>NCT00754780</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1</brief_title>
  <official_title>Phase II Clinical Trial of Pirfenidone for the Treatment of Patients With Neurofibromatosis Type I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a phase II, open label trial of oral Pirfenidone in 24 adult patients with&#xD;
      neurofibromatosis type 1.&#xD;
&#xD;
      Pirfenidone is a new, broad-spectrum anti-fibrotic drug, with proven in vitro and in vivo&#xD;
      negative effects on fibroblast growth and collagen matrix synthesis. Human studies indicate&#xD;
      promising therapeutic effects in arresting and reversing fibrosis in a variety of different&#xD;
      conditions, where the excessive formation of fibrous tissue is a major pathogenic mechanism.&#xD;
      Since the fibrous tissue is a significant component of neurofibroma, reduction of fibrosis&#xD;
      could diminish tumor progression and lead to tumor shrinkage. Therefore, Pirfenidone is an&#xD;
      excellent candidate for the treatment of plexiform neurofibromas and surgically unresectable&#xD;
      tumors in patients with NF1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific aims of this study are:&#xD;
&#xD;
        1. To evaluate efficacy of Pirfenidone in NF1 patients with disfiguring or disabling&#xD;
           plexiform neurofibroma (PN) and spinal neurofibromas (SN)&#xD;
&#xD;
        2. To determine the acute, subacute and chronic toxicity of Pirfenidone in patients with&#xD;
           NF1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor volume</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Neurofibromatosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Capsule 800 mg TID, oral</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of neurofibromatosis type I, based on clinical criteria (NIH Consensus&#xD;
             Development Conference, 1988). Tumors will not be confirmed histologically, since the&#xD;
             biopsy could cause a change in tumor growth and such interfere with effect of&#xD;
             Pirfenidone treatment.&#xD;
&#xD;
          -  Male or female patients&#xD;
&#xD;
          -  Age 18 years old&#xD;
&#xD;
          -  All patients should be mentally capable of signing the consent form or should have a&#xD;
             legal guardian to provide consent&#xD;
&#xD;
          -  Patients who are experiencing symptoms from neurofibromatous lesions and who refuse&#xD;
             surgery or are not good surgical candidates, such as those with plexiform neurofibroma&#xD;
             who are experiencing significant discomfort, disfigurement or nerve compression or&#xD;
&#xD;
          -  Presence of multiple spinal neurofibromas in which the surgical removal would carry a&#xD;
             major risk for spinal cord damage.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumors for which surgical removal could lead to permanent (or long-term) relief of&#xD;
             symptoms&#xD;
&#xD;
          -  Patients with open skin lesions and patients for whom surgery is being contemplated or&#xD;
             who had surgery less than 4 weeks from starting treatment&#xD;
&#xD;
          -  Patients for whom biopsy is warranted for suspected malignancies&#xD;
&#xD;
          -  Individuals younger than 18 years&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Inability to have MR imaging (e.g. claustrophobia, pacemaker or allergy to contrast&#xD;
             dye, if administration is needed for neurofibroma imaging)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dusica Babovic-Vuksanovic, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>September 16, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dusica Babovic-Vuksanovic, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>NF1</keyword>
  <keyword>plexiform neurofibroma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

